BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 18775759)

  • 1. Evidence-based dose-response assessment for thyroid tumorigenesis from acrylamide.
    Dourson M; Hertzberg R; Allen B; Haber L; Parker A; Kroner O; Maier A; Kohrman M
    Regul Toxicol Pharmacol; 2008 Dec; 52(3):264-89. PubMed ID: 18775759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acrylamide: review of toxicity data and dose-response analyses for cancer and noncancer effects.
    Shipp A; Lawrence G; Gentry R; McDonald T; Bartow H; Bounds J; Macdonald N; Clewell H; Allen B; Van Landingham C
    Crit Rev Toxicol; 2006; 36(6-7):481-608. PubMed ID: 16973444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amended final report on the safety assessment of polyacrylamide and acrylamide residues in cosmetics.
    Int J Toxicol; 2005; 24 Suppl 2():21-50. PubMed ID: 16154914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acrylamide carcinogenicity.
    Klaunig JE
    J Agric Food Chem; 2008 Aug; 56(15):5984-8. PubMed ID: 18624430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response modeling of in vivo genotoxicity data for use in risk assessment: some approaches illustrated by an analysis of acrylamide.
    Allen B; Zeiger E; Lawrence G; Friedman M; Shipp A
    Regul Toxicol Pharmacol; 2005 Feb; 41(1):6-27. PubMed ID: 15649824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical review of dose-response options for F344 rat mammary tumors for acrylamide - additional insights based on mode of action.
    Maier A; Kohrman-Vincent M; Hertzberg R; Allen B; Haber LT; Dourson M
    Food Chem Toxicol; 2012 May; 50(5):1763-75. PubMed ID: 22366097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The carcinogenicity of acrylamide.
    Rice JM
    Mutat Res; 2005 Feb; 580(1-2):3-20. PubMed ID: 15668103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addressing nonlinearity in the exposure-response relationship for a genotoxic carcinogen: cancer potency estimates for ethylene oxide.
    Kirman CR; Sweeney LM; Teta MJ; Sielken RL; Valdez-Flores C; Albertini RJ; Gargas ML
    Risk Anal; 2004 Oct; 24(5):1165-83. PubMed ID: 15563286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acrylamide: Consideration of species differences and nonlinear processes in estimating risk and safety for human ingestion.
    Gargas ML; Kirman CR; Sweeney LM; Tardiff RG
    Food Chem Toxicol; 2009 Apr; 47(4):760-8. PubMed ID: 19166901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acrylamide does not induce tumorigenesis or major defects in mice in vivo.
    Jin L; Chico-Galdo V; Massart C; Gervy C; De Maertelaere V; Friedman M; Van Sande J
    J Endocrinol; 2008 Aug; 198(2):301-7. PubMed ID: 18483202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk assessment of acrylamide in foods.
    Dybing E; Sanner T
    Toxicol Sci; 2003 Sep; 75(1):7-15. PubMed ID: 12805639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer risk assessment for 1,3-butadiene: data integration opportunities.
    Preston RJ
    Chem Biol Interact; 2007 Mar; 166(1-3):150-5. PubMed ID: 16647696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of human relevance and mode of action for tunica vaginalis mesotheliomas resulting from oral exposure to acrylamide.
    Haber LT; Maier A; Kroner OL; Kohrman MJ
    Regul Toxicol Pharmacol; 2009 Mar; 53(2):134-49. PubMed ID: 19166893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer dose--response assessment for acrylonitrile based upon rodent brain tumor incidence: use of epidemiologic, mechanistic, and pharmacokinetic support for nonlinearity.
    Kirman CR; Gargas ML; Marsh GM; Strother DE; Klaunig JE; Collins JJ; Deskin R
    Regul Toxicol Pharmacol; 2005 Oct; 43(1):85-103. PubMed ID: 16099568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-year carcinogenicity study of acrylamide in Wistar Han rats with in utero exposure.
    Maronpot RR; Thoolen RJ; Hansen B
    Exp Toxicol Pathol; 2015 Feb; 67(2):189-95. PubMed ID: 25553597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide.
    McCarroll N; Keshava N; Cimino M; Chu M; Dearfield K; Keshava C; Kligerman A; Owen R; Protzel A; Putzrath R; Schoeny R
    Environ Mol Mutagen; 2008 Mar; 49(2):117-31. PubMed ID: 18240158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of acrylamide on some hormones and endocrine tissues in male rats.
    Hamdy SM; Bakeer HM; Eskander EF; Sayed ON
    Hum Exp Toxicol; 2012 May; 31(5):483-91. PubMed ID: 21878450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of mechanisms of acrylamide carcinogenicity.
    Besaratinia A; Pfeifer GP
    Carcinogenesis; 2007 Mar; 28(3):519-28. PubMed ID: 17234719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesotheliomas of tunica vaginalis testis of Fischer 344 (F344) rats treated with acrylamide: a light and electron microscopy study.
    Damjanov I; Friedman MA
    In Vivo; 1998; 12(5):495-502. PubMed ID: 9827357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating genotoxicity data to identify a mode of action and its application in estimating cancer risk at low doses: A case study involving carbon tetrachloride.
    Eastmond DA
    Environ Mol Mutagen; 2008 Mar; 49(2):132-41. PubMed ID: 18213651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.